Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of acute and chronic inflammation
Laboratory studyOther animalsWith adelmidrol (a PEA analogue, tested alone)
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with carrageenan-induced paw edema (acute) and collagen-induced arthritis (chronic)
- Dose used in the study
- Adelmidrol; dose not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Paw edema, hyperalgesia, NF-kB pathway activation, joint and paw histopathology, oxidative damage, proinflammatory cytokines/chemokines, and the roles of PPAR-alpha and PPAR-gamma.
What the authors reported
Adelmidrol markedly reduced carrageenan-induced paw edema, hyperalgesia and NF-kB activation; a PPAR-gamma antagonist blocked this, while lack of PPAR-alpha did not change it. In chronic arthritis, adelmidrol improved clinical signs and joint histopathology and reduced oxidative damage and cytokine/chemokine production, again reversed by the PPAR-gamma antagonist.
Limits of this study
Mouse models of acute and chronic inflammation; it cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 27599446 · doi:10.1016/j.bcp.2016.09.001
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.